Details

<p> </p><p>Antibody-drug conjugates (ADCs) stand at the verge of a transformation.&nbsp; Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges.&nbsp; This volume focuses on the next generation of ADCs and the innovations that will enable them.&nbsp; The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies.&nbsp; While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.</p><p> The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.&nbsp; However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing.&nbsp; The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies.&nbsp; These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.</p><p></p>